Stock Price Forecast

March 28, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Eyenovia Inc chart...

About the Company

eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.

Exchange

NASDAQ

Website

eyenoviabio.com

$2M

Total Revenue

44

Employees

$45M

Market Capitalization

-1.49

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $EYEN News

Eyenovia, Inc. (NASDAQ:EYEN) Q4 2023 Earnings Call Transcript

10d ago, source:

Q4 2023 Earnings Call March 18, 2024 Eyenovia, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of ...

Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates

10d ago, source: Hosted on MSN

Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago. These figures are ...

NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals

16d ago, source:

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare ...

Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

10d ago, source:

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced its financial and operating results for the fourth quarter and ...

US FDA approves Eyenovia's eye drug, Formosa Pharma says

24d ago, source:

The U.S. Food and Drug Administration approved Eyenovia's eye drops to reduce inflammation and pain in patients who have undergone eye surgery, Formosa Pharmaceuticals said on Monday.

Eyenovia’s Strategic Commercial Synergy and Growth Potential Reinforce Buy Rating

10d ago, source:

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Eyenovia (EYEN – Research Report), with a ...

Earnings Preview For Eyenovia

13d ago, source:

Analysts estimate that Eyenovia will report an earnings per share (EPS) of $-0.17. Eyenovia bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide ...

Over $2M Bet On NextNav? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

on MSN ago, source:

The Dow Jones index closed higher by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their ...

Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th

18d ago, source:

Company to host an investor conference call and webcast at 4:30pm EDTNEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic pharmaceutical technology ...

Stocks Settle Lower as Bond Yields Climb on Inflation Concerns

13d ago, source:

Costar Group ( CSGP) closed up more than +8% to lead gainers in the S&P 500 and the Nasdaq 100 after the National Association of Realtors agreed to a $418 million deal to settle litigation over ...

Stocks Rally on Strength in Technology Stocks

1y ago, source:

The S&P 500 Index ( $SPX) ( SPY) this morning is up +1.00%, the Dow Jones Industrials Index ( $DOWI ) ( DIA) is up +0.24%, and the Nasdaq 100 Index ( $IUXX) ( QQQ) is up +1.67%.

Q4 2023 Eyenovia Inc Earnings Call

10d ago, source:

Matthew Caufield; Analyst; H.C. Wainwright & Co., LLC ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...